Cellectis S.A. announced that Mrs. Cécile Chartier has been appointed as director of the Company’s board of director. The terms of office of Mr. Hervé Hoppenot and Mrs. Annick Schwebig ended just after the June 27, 2023 Meeting. Cécile Chartier currently serves as Chief Scientific Officer at NextVivo Inc. Prior to her tenure at NextVivo, Dr. Chartier was Vice President of Research at Iovance Biotherapeutics Inc. where she led the development of next generation tumor-infiltrating lymphocytes (TIL) therapies through research to early-stage clinical trials.

Prior to this, she spent 12 years at OncoMed Pharmaceuticals, where she served as Senior Director of Target Validation and led multiple antibody therapeutics project teams through Research and Development to IND filing. She also worked at Shering (US Berlex) and Transgene (France), where she focused on gene therapy. Dr. Chartier obtained her Ph.D. in molecular biology from the Université Louis Pasteur in Strasbourg, France and pursued a post-doctoral training at Harvard Medical School.